Limited Competition: National Biocontainment Laboratories (NBLs) Operations Support (UC7 Clinical Trial Not Allowed)
Limited Competition: National Biocontainment Laboratories (NBLs) Operations Support (UC7 Clinical Trial Not Allowed)
批准号:
10634557
负责人:
Gary Kobinger
金额:
$1150.0万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
未结题
起止时间:
2011-05-31 至 2026-05-31
关键词:
AddressAerosolsApplied ResearchArbovirusesArthropod VectorsBasic ScienceBiotechnologyBioterrorismCaringClinical TrialsCollectionCommunicable DiseasesCommunitiesContainmentDangerousnessDevelopmentDiagnosticEducationEmergency SituationEmerging Communicable DiseasesEnsureEnvironmentEquipmentEventFacultyFundingGoalsGuidelinesHumanInfrastructureInternationalLaboratoriesLaboratory AnimalsLaboratory ResearchLicensureMaintenanceMedicalMentorsModernizationMusNational Institute of Allergy and Infectious DiseasePoliciesPreventivePublic HealthQualifyingQuality ControlReagentRecordsRegulationReproducibilityResearchResearch InfrastructureResearch PersonnelResolutionResourcesRiskScientistSecureStudentsTexasTrainingUnited StatesUnited States Food and Drug AdministrationUnited States National Institutes of HealthUnited States Public Health ServiceUniversitiesVaccinesValidationVirusVisualizationWorkZoonosesanimal careanimal rulebiodefensebiosecuritycareercostdisease transmissionexperienceglobal healthimaging capabilitiesinstrumentinterestmedical countermeasurenext generationnonhuman primatenovelnovel therapeuticsoperationpathogenproduct developmentprogramspublic health emergencyrecruitresearch facilityskillstherapeutic developmenttool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
The goal of this project is to maintain the Galveston National Laboratory (GNL) at the
University of Texas Medical Branch as a part of the NIAID Biodefense Facilities Network
to provide access to maximum containment research facilities for NIAID funded
investigators, academic collaborators from across the nation and around the world,
commercial partners and others as appropriate. This high containment research
infrastructure and associated facilities is required to safely and securely conduct
research that will facilitate the discovery and development of therapeutics, diagnostics
and vaccines for dangerous pathogens requiring biocontainment. This unique resource
is also a critical resource to educate the next generation of experts in infectious
diseases of global health importance. The GNL actively responds to national public
health emergencies by providing rapid assistance in diagnostics, sharing of critical
reagents, and contributing to the discovery and development of effective medical
countermeasures. To achieve this goal, the GNL maintains cores focused on supporting
safe and secure operations and maintenance of maximum containment research
facilities and to provide unique resources and tools to investigators working in
biocontainment to allow them to rapidly, safely and securely address emerging
infectious diseases and bioterrorism threats. Unique capabilities include the ability to
generate and quantify aerosol challenges of laboratory animals from mice to non-human
primates, access to arthropod vector colonies to support zoonotic disease transmission
studies, and state-of-the-art imaging capabilities to visualize findings, among many
others. Working together, GNL teams conduct basic and applied research that can
transition original discoveries from concept to final product development, validation and
licensure.
期刊论文(42)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1172/jci164946
发表时间:
2023-02-01
期刊:
JOURNAL OF CLINICAL INVESTIGATION
影响因子:
15.9
作者:
[Woolsey, Courtney, Borisevich, Viktoriya, Fears, Alyssa C., Agans, Krystle N., Deer, Daniel J., Prasad, Abhishek N., O'Toole, Rachel, Foster, Stephanie L., Dobias, Natalie S., Geisbert, Joan B., Fenton, Karla A., Cross, Robert W., Geisbert, Thomas W.]
通讯作者:
Geisbert, Thomas W.
DOI:
10.3390/vaccines10101582
发表时间:
2022-09-21
期刊:
Vaccines
影响因子:
7.8
作者:
[Cooper CL, Morrow G, Yuan M, Coleman JW, Hou F, Reiserova L, Li SL, Wagner D, Carpov A, Wallace-Selman O, Valentin K, Choi Y, Wilson A, Kilianski A, Sayeed E, Agans KN, Borisevich V, Cross RW, Geisbert TW, Feinberg MB, Gupta SB, Parks CL]
通讯作者:
Parks CL
A Recombinant Vesicular Stomatitis Virus-Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection.
重组水泡性口炎病毒疫苗可提供针对本迪布焦埃博拉病毒感染的暴露后保护。
DOI:
10.1093/infdis/jiad207
发表时间:
2023
期刊:
The Journal of infectious diseases
影响因子:
--
作者:
[Woolsey,Courtney, Strampe,Jamie, Fenton,KarlaA, Agans,KrystleN, Martinez,Jasmine, Borisevich,Viktoriya, Dobias,NatalieS, Deer,DanielJ, Geisbert,JoanB, Cross,RobertW, Connor,JohnH, Geisbert,ThomasW]
通讯作者:
Geisbert,ThomasW
DOI:
10.1038/s41467-021-22132-0
发表时间:
2021-03-25
期刊:
Nature communications
影响因子:
16.6
作者:
[Cross RW, Bornholdt ZA, Prasad AN, Borisevich V, Agans KN, Deer DJ, Abelson DM, Kim DH, Shestowsky WS, Campbell LA, Bunyan E, Geisbert JB, Fenton KA, Zeitlin L, Porter DP, Geisbert TW]
通讯作者:
Geisbert TW
DOI:
10.1038/s41590-020-00835-8
发表时间:
2021-01
期刊:
Nature immunology
影响因子:
30.5
作者:
[Woolsey C, Borisevich V, Prasad AN, Agans KN, Deer DJ, Dobias NS, Heymann JC, Foster SL, Levine CB, Medina L, Melody K, Geisbert JB, Fenton KA, Geisbert TW, Cross RW]
通讯作者:
Cross RW
共 23 条
Pandemic Preparedness: Biocontainment Facility Upgrade and Integration at UTMB/Galveston National Laboratory
-
批准号:10611097
-
项目类别:
-
资助金额:$713.18万
-
财政年份:2022
-
负责人:Gary Kobinger
-
依托单位:
Limited Competition: National Biocontainment Laboratories (NBLs) Operations Support (UC7 Clinical Trial Not Allowed)
-
批准号:10221393
-
项目类别:
-
资助金额:$1150.0万
-
财政年份:2011
-
负责人:Gary Kobinger
-
依托单位:
Limited Competition: National Biocontainment Laboratories (NBLs) Operations Support (UC7 Clinical Trial Not Allowed)
-
批准号:10441384
-
项目类别:
-
资助金额:$1150.0万
-
财政年份:2011
-
负责人:Gary Kobinger
-
依托单位:
海外基金